Akebia Therapeutics receives patent for Vafseo until 2043 By Investing.com
Akebia Therapeutics (NASDAQ: AKBA) announced that the United States Patent and Trademark Office has granted a new patent for Vafseo (vadadustat), extending protection until January 18, 2043. This patent covers a method of treatment related to modulating drug-drug interactions with vadadustat. Vafseo, approved by the FDA in March 2024 for anemia due to chronic kidney disease in adult dialysis patients, is commercially available in the U.S. and approved in 37 countries.
Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
Akebia Therapeutics has been granted a new U.S. patent for Vafseo (vadadustat), extending its intellectual property protection until 2043. This patent, relating to the modulation of drug-drug interactions, strengthens Akebia's portfolio for Vafseo, an oral treatment for anemia due to chronic kidney disease in dialysis patients. The company aims for Vafseo to become the standard of care, supported by clinical outcomes and this reinforced patent protection.
Akebia Therapeutics receives patent for Vafseo until 2043
Akebia Therapeutics announced that the U.S. Patent and Trademark Office granted a new patent for Vafseo (vadadustat), extending its term until January 18, 2043. This patent covers a method of treatment related to modulating drug-drug interactions with vadadustat. Vafseo, approved in March 2024 for anemia in chronic kidney disease patients on dialysis, is also approved in 37 other countries.
Akebia Therapeutics Announces New Vafseo Patent Extending Intellectual Property Protection to 2043
Akebia Therapeutics has announced the grant of a new patent for its drug Vafseo (vadadustat), extending its intellectual property protection until January 18, 2043. This patent, related to drug-drug interactions, is eligible for listing in the Orange Book and is expected to enhance Vafseo's long-term market value. Vafseo, approved in March 2024, is the only oral hypoxia-inducible factor-prolyl hydroxylase inhibitor available in the U.S. for dialysis-dependent adults with anemia due to chronic kidney disease.
Akebia Therapeutics Secures $140 Million Senior Secured Term Loan from Symbiotic Capital
Akebia Therapeutics has secured a senior secured term loan facility of up to $140 million from Symbiotic Capital, replacing its prior $55 million Kreos term loan. The new five-year loan matures in November 2031, carries a variable interest rate, and includes the issuance of warrants for 3,441,352 common stock shares to affiliates of the lenders. The initial $60 million tranche provided approximately $58.6 million in net proceeds, used primarily to repay the previous debt.
Akebia Therapeutics (NASDAQ:AKBA) Cut to Strong Sell at Wall Street Zen
Wall Street Zen has downgraded Akebia Therapeutics (NASDAQ:AKBA) from "sell" to "strong sell," despite MarketBeat reporting an average analyst rating of "Hold" with a $3.50 price target. The company's stock is trading near its 12-month low, and while it met EPS estimates, its revenue fell short of forecasts. Institutional investors have made significant changes to their holdings in the biopharmaceutical company.
Akebia secures $60M loan facility, repays BlackRock debt By Investing.com
Akebia Therapeutics, Inc. has secured a new senior secured term loan facility of $60 million from Symbiotic Capital, with the potential for an additional $80 million. The company utilized the initial $60 million to fully repay its existing $55 million debt with BlackRock. This new financing is expected to enhance Akebia's operational flexibility and provides non-dilutive capital to advance its strategic initiatives, reaffirming its cash runway guidance for at least two years.
Akebia lands up to $140M loan facility; clears $55M BlackRock debt
Akebia Therapeutics has secured a senior secured term loan facility of up to $140 million with Symbiotic Capital, receiving an initial $60 million tranche. The company used these initial proceeds to fully repay its $55 million loan from BlackRock. Akebia reaffirmed its cash runway guidance of at least two years, and its shares saw a nearly 2% rise in premarket trading.
Form 8K Akebia Therapeutics Inc For: 16 November By Investing.com
Akebia Therapeutics Inc. (AKBA) filed a Form 8K on November 16, 2026. This filing typically reports significant events that shareholders should know about. The article from Investing.com provides this brief announcement and includes market data for various indices, commodities, and shares.
A new loan carries at least 11.5% interest for Akebia Therapeutics (AKBA).
Akebia Therapeutics has secured a new senior secured term loan facility worth up to $140 million with Symbiotic Capital. An initial $60 million tranche was funded on November 12, 2026, with proceeds used to repay a prior $55 million loan from BlackRock. The new loan carries a variable annual interest rate of at least 11.5% and Akebia also issued warrants for 3,441,352 shares of common stock.
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Target Lowered at Piper Sandler
Piper Sandler has lowered its price target for Akebia Therapeutics (NASDAQ:AKBA) to $2.00 but maintained an "overweight" rating, suggesting a significant upside. Analyst sentiment is mixed, with an average "Hold" rating and a $3.50 target. The company recently met EPS estimates but fell short on revenue in its latest quarterly results.
Form 8K Akebia Therapeutics Inc For: 16 November By Investing.com
This article announces that Akebia Therapeutics Inc. filed a Form 8K on November 16, 2026. The filing is an official document that companies must submit to the U.S. Securities and Exchange Commission (SEC) to announce significant events that shareholders should know about. The brief piece indicates that more detailed information would typically be contained within the Form 8K itself.
Akebia Therapeutics Secures Up to $140 Million Five-Year Loan Facility From Symbiotic
Akebia Therapeutics has secured a new senior secured term loan facility with Symbiotic Capital for up to $140 million, replacing its previous loan with Kreos. The initial funding includes a $60 million loan, with Akebia receiving approximately $58.6 million in net proceeds. This new agreement provides the company with additional funding and financial flexibility, maturing on November 12, 2031.
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced a new senior secured term loan facility with Symbiotic Capital worth up to $140 million. An initial $60 million tranche was fully funded and used to repay a $55 million BlackRock loan. This financing aims to enhance operational flexibility, provide potential access to additional non-dilutive capital, and reaffirms Akebia's cash runway guidance of at least two years.
The Consensus EPS Estimates For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Fell Dramatically
Analysts have significantly cut their revenue and earnings per share (EPS) estimates for Akebia Therapeutics, Inc., indicating a pessimistic outlook for the company's future performance. The consensus revenue estimate for 2027 was reduced by 19% to US$108m, and projected losses per share increased by 9% to US$0.35. This downgrade, coupled with a falling price target, suggests potential investor caution regarding Akebia Therapeutics' prospects, which are expected to decline faster than the broader industry.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Akebia Therapeutics (NASDAQ:AKBA) recently reported disappointing quarterly results, leading analysts to significantly cut their 2027 revenue estimates by 21% and increase loss per share forecasts to US$0.35. The consensus price target also dropped 17% to US$3.25, reflecting concerns about the company's declining revenues and underperformance compared to the broader industry. Analysts highlight increasing losses and a projected annual revenue decline of 38% until the end of 2027, contrasting with an expected 22% growth for peers.
Akebia Therapeutics Reports 277.7M Shares Outstanding in Q3 2026 10-Q Filing
Akebia Therapeutics, Inc. submitted its Q3 2026 10-Q filing, revealing 277.7 million shares outstanding as of November 2, 2026. The report details the company's marketed products, Vafseo and Auryxia, noting Auryxia's loss of exclusivity in March 2025 and ongoing efforts to secure Vafseo reimbursement. Additionally, the filing mentions pipeline candidates ebribafusp, praliciguat, and AKB-9090, alongside cautionary forward-looking statements.
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
Akebia Therapeutics (AKBA) reported lower Q3 revenue and a net loss due to declining Auryxia sales and inventory reductions for Vafseo, despite a significant increase in Vafseo patients. The company anticipates continued patient growth for Vafseo in Q4, with a focus on mid-sized dialysis providers and a slow rollout by larger organizations like DaVita ahead of a 2027 reimbursement change. Akebia also highlighted positive trial results for Vafseo and is exploring pipeline developments for other kidney diseases.
Akebia Therapeutics Q3 2026 Earnings Call Transcript
Akebia Therapeutics reported Q3 2026 Vafseo net product revenues of $14.8 million, a 3% increase year-over-year, despite a 140% patient growth, primarily due to inventory drawdown influenced by lower dosing and dialysis compliance rates. Total revenues declined to $36.9 million from $58.8 million due to generic competition impacting Auryxia. The company remains optimistic about Vafseo becoming a standard of care, supported by positive VOICE trial data showing a 10% reduction in hospitalizations and ongoing post-TDAPA contract negotiations with large dialysis organizations like DaVita.
Akebia Therapeutics reports noninferiority in vadadustat dosing trial
Akebia Therapeutics announced positive results from its 353-patient VOCAL Phase 3 trial, demonstrating noninferiority for a three-times-weekly vadadustat regimen in maintaining hemoglobin levels in hemodialysis patients. While vadadustat (Vafseo) is currently approved for once-daily use, these new findings support an alternative dosing schedule, even though the estimated difference in hemoglobin change favored the comparator drug, Mircera. The company also reported third-quarter financial results, including $14.8 million in Vafseo revenue, and discussed its cash position and other pipeline developments.
A trial-tested three-times-weekly anemia drug dose was no worse than standard care at maintaining hemoglobin.
Akebia Therapeutics announced positive topline results from its VOCAL trial, demonstrating that three-times-weekly dosing of vadadustat met its primary endpoint of non-inferiority to standard erythropoiesis-stimulating agents (ESA) in maintaining hemoglobin levels in patients with anemia due to chronic kidney disease receiving hemodialysis. The trial, involving 353 patients, showed similar rates of treatment-emergent serious adverse events between vadadustat and ESA. While the three-times-weekly dosing is investigational, the company's branded form, Vafseo, is approved for once-daily administration.
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
Akebia Therapeutics announced positive topline results from its VOCAL trial, demonstrating that vadadustat dosed three times per week (TIW) met its primary endpoint of non-inferiority to erythropoiesis-stimulating agents (ESA) in maintaining hemoglobin levels in chronic kidney disease patients on hemodialysis. The trial also showed similar rates of treatment-emergent serious adverse events between vadadustat and ESA. These results complement existing data on vadadustat, including its approved once-daily formulation, Vafseo®, and provide additional evidence for an investigational TIW dosing regimen.
Vafseo patients rise about 140% as Akebia Therapeutics (AKBA) swings to a quarterly loss.
Akebia Therapeutics (AKBA) reported a net loss of $14.4 million in Q3 2026, a significant drop from a net income of $0.5 million in Q3 2025, primarily due to lower Auryxia revenues. Despite this, Vafseo net product revenues increased slightly to $14.8 million, with active patients growing by approximately 140% year-over-year to 11,500. The company also highlighted positive data from its VOCAL and VOICE trials for vadadustat and the initiation of a Phase 2 trial for ebribafusp alfa, while maintaining a strong cash position to fund operations for at least two years.
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics (Nasdaq: AKBA) reported its Q3 2026 financial results, including Vafseo® (vadadustat) net product revenues of $14.8 million and approximately 11,500 patients on therapy. The company highlighted positive VOICE and VOCAL trial data demonstrating improved safety outcomes and non-inferiority for vadadustat. Akebia also initiated a Phase 2 trial for ebribafusp alfa in rare kidney diseases and maintained a strong cash position of $159.3 million.
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics reported its third-quarter 2026 financial results, highlighting a significant increase in Vafseo® (vadadustat) patients to approximately 11,500, up 140% from Q3 2025. The company also announced positive VOICE trial data demonstrating improved safety outcomes for vadadustat compared to ESAs and topline VOCAL data showing non-inferiority in maintaining hemoglobin. Despite a decrease in total revenues due to lower Auryxia sales, Akebia maintains a strong financial position and is advancing its rare kidney disease pipeline.
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
Akebia Therapeutics announced positive topline results from its VOCAL trial, demonstrating that vadadustat, when dosed three times per week (TIW), met the primary endpoint of non-inferiority to erythropoiesis-stimulating agents (ESA) in maintaining hemoglobin levels in dialysis patients with anemia due to chronic kidney disease (CKD). The trial also showed similar rates of treatment-emergent serious adverse events between vadadustat and ESA. These findings complement existing clinical evidence and provide additional data on an investigational TIW dosing regimen for vadadustat, which is already approved for once-daily use.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Price Target of $3.90
Akebia Therapeutics (NASDAQ:AKBA) has an average 12-month price target of $3.90, with analysts issuing a consensus "Hold" rating based on four buy, two hold, and one sell recommendation. The company's shares opened at $0.71, near its 52-week low, and reported quarterly adjusted losses of $0.02 per share, beating estimates. Institutional investors collectively own approximately 33.9% of the company's stock.
Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at Wall Street Zen
Akebia Therapeutics (NASDAQ:AKBA) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. Despite mixed analyst sentiment, the consensus target price for AKBA is $3.90, and the company recently exceeded its quarterly earnings and revenue expectations. Institutional investors have also shown increased interest, modifying their holdings in the biopharmaceutical company.
Akebia Therapeutics, Inc. (AKBA) Seasonal returns chart
This article provides a seasonal returns chart for Akebia Therapeutics, Inc. (AKBA), showing the average monthly price return between 2016 and 2026. It includes current stock information, indicating a price of 0.7065 USD, with a recent decline of 4.81%. The page also highlights after-hours trading activity.
Akebia Therapeutics, Inc. (AKBA) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Akebia Therapeutics, Inc. (AKBA), displaying the average monthly price return from 2016 to 2026. It includes current stock information, showing a closing price of $0.7065 with a 4.81% decrease, and an after-hours price of $0.7000 with a 0.92% decrease as of October 30.
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics (AKBA) plans to release its third-quarter 2026 financial results on November 5, 2026, before financial markets open. The company will host a conference call at 8:00 a.m. EST on the same day to discuss these results and recent business highlights. A live webcast and archive of the call will be available via the Investors section of Akebia’s website.
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its third-quarter 2026 financial results on Thursday, November 5, 2026, before financial markets open. The company will host a conference call on the same day at 8:00 a.m. EST to discuss these results and recent business developments. Interested parties can register for the call via a provided link or access a live webcast through the Investors section of Akebia's website.
AKBA Q3'26 Earnings: EPS estimate is (0.04) USD
Akebia Therapeutics, Inc. (AKBA) is scheduled to release its Q3'26 earnings on October 29. Analysts estimate revenue to be $46.94 million and earnings per share (EPS) at ($0.04). The article includes a table comparing reported and estimated revenue and EPS from Q3'25 through Q3'26, highlighting the company's past performance against estimates.
Akebia Therapeutics, Inc. Estimates – NASDAQ:AKBA
This article provides a financial overview of Akebia Therapeutics, Inc. (NASDAQ:AKBA) on TradingView. It highlights where to find reported financial data and analyst estimates, including income statements, balance sheets, and cash flow statements, and allows for comparison of actual results against average, high, and low estimates. The platform also offers tools to visualize trends over time for the company's financials.
Akebia Therapeutics receives Nasdaq notice for minimum bid price deficiency
Akebia Therapeutics (NASDAQ:AKBA) has received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until April 19, 2027, to regain compliance, potentially through a reverse stock split. This announcement follows mixed Q2 2026 results where Akebia surpassed EPS expectations but missed revenue projections.
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Sell"
Akebia Therapeutics (NASDAQ:AKBA) was downgraded by Wall Street Zen from a "hold" to a "sell" rating, despite a divided analyst consensus that still leans towards "hold" with an average price target of $3.90. The stock recently opened at $0.57, near its 12-month low, and has faced negative net margin and return on equity, though its latest quarterly earnings beat analyst expectations. Institutional investors currently hold 33.92% of the company's shares.
After 30 business days below $1, Akebia Therapeutics (Nasdaq: AKBA) gets a compliance deadline.
Akebia Therapeutics (AKBA) has received a Nasdaq deficiency notice because its stock price has been below $1.00 for 30 consecutive business days. The company has until April 19, 2027, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Akebia is evaluating its options, including a potential reverse stock split, to address this issue and avoid delisting.
Akebia Therapeutics receives Nasdaq notice for minimum bid price deficiency By Investing.com
Akebia Therapeutics (NASDAQ:AKBA) has received a notice from Nasdaq regarding its common stock trading below the minimum $1.00 bid price for 30 consecutive business days. The company has 180 calendar days, until April 19, 2027, to regain compliance, potentially through a reverse stock split. This news follows mixed Q2 2026 results where Akebia beat EPS expectations but missed revenue targets, though analysts like H.C. Wainwright maintain a "Buy" rating.
Form 8K Akebia Therapeutics Inc For: 23 October By Investing.com
Akebia Therapeutics Inc. filed a Form 8K on October 23, 2026. The article from Investing.com provides this brief notification without further details on the content of the filing. It also notes Akebia's stock performance, showing a 13.58% increase.
Form 8K Akebia Therapeutics Inc For: 23 October By Investing.com
This article from Investing.com announces that Akebia Therapeutics Inc. filed a Form 8K on October 23. The Form 8K is a crucial document that companies file with the SEC to announce major events that shareholders should know about. No specific details about the content of the Form 8K are provided in this brief announcement.
Akebia Therapeutics receives Nasdaq notice for minimum bid price deficiency By Investing.com
Akebia Therapeutics (NASDAQ:AKBA) has received a Nasdaq deficiency letter because its stock price closed below the minimum $1.00 bid price for 30 consecutive business days. The company has 180 calendar days to regain compliance and may consider options like a reverse stock split. This news follows a mixed Q2 2026 earnings report and an reiterated Buy rating from H.C. Wainwright.
Akebia Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Akebia Therapeutics (AKBA) has received a notice from Nasdaq that its stock has fallen below the $1.00 minimum bid price for 30 consecutive business days, violating a listing rule. The company has until April 19, 2027, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. This notice does not immediately affect its listing.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics has reported inducement grants of stock options and restricted stock units to new employees. These grants were made under Nasdaq Listing Rule 5635(c)(4) as an inducement material to their employment. The compensation committee approved these grants on October 18, 2026.
The commercial chief at Akebia Therapeutics (AKBA) plans to resign for personal reasons.
Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics (AKBA), is set to resign on November 6, 2026, due to personal reasons. Following his resignation, he will enter a consulting agreement with the company to provide advisory services until April 30, 2027. This information was disclosed in an 8-K filing, indicating a moderate impact and neutral sentiment on the company.
Nicholas Grund to Resign as Akebia's Chief Commercial Officer, Will Serve as Consultant
Nicholas Grund, Akebia Therapeutics' Senior Vice President and Chief Commercial Officer, will resign from his position effective November 6, 2026, due to personal reasons. He will then transition into a consulting role, providing services to Akebia through April 30, 2027. This information is based on an SEC filing by Akebia Therapeutics, Inc. (AKBA).
Akebia Therapeutics Q3 2026 Earnings Date and Estimates
Akebia Therapeutics (AKBA) is scheduled to report its Q3 2026 earnings on Monday, November 9, 2026, after market close, with a conference call at 8:00 AM ET. Analysts expect the company to report earnings of -$0.0360 per share on revenue of $46.94 million. The article also provides historical earnings data and recent news headlines related to Akebia Therapeutics.
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Akebia Therapeutics, Inc. announced that its CEO, Chief R&D and Medical Officer, and Chief Financial and Chief Business Officer will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. Management plans to discuss its commercial products and clinical-stage pipeline assets for rare kidney diseases. Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals with kidney disease.
Commercial products and rare kidney disease drug candidates are on Akebia's agenda at online meetings.
Akebia Therapeutics (AKBA) announced that its CEO, John P. Butler, along with other key executives, will participate in one-on-one investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. Management plans to discuss the company's commercial products and its clinical-stage pipeline assets designed for rare kidney diseases. The announcement also noted Akebia's stock performance on the day the news was released.
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced that its CEO, Chief R&D and Medical Officer, and CFO/CBO will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. During these meetings, management plans to discuss the company's commercial products and its clinical-stage pipeline focused on rare kidney diseases. Akebia Therapeutics is a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease.
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Akebia Therapeutics, Inc. announced that its CEO, Chief R&D and Medical Officer, and Chief Financial and Chief Business Officer will participate in one-on-one investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. Management will discuss commercial products and clinical-stage pipeline assets for rare kidney diseases. Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of people with kidney disease.